Cargando…

Impact of a Panel of 88 Single Nucleotide Polymorphisms on the Risk of Breast Cancer in High-Risk Women: Results From Two Randomized Tamoxifen Prevention Trials

PURPOSE: At least 94 common single nucleotide polymorphisms (SNPs) are associated with breast cancer. The extent to which an SNP panel can refine risk in women who receive preventive therapy has not been directly assessed previously. MATERIALS AND METHODS: A risk score on the basis of 88 SNPs (SNP88...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cuzick, Jack, Brentnall, Adam R., Segal, Corrinne, Byers, Helen, Reuter, Caroline, Detre, Simone, Lopez-Knowles, Elena, Sestak, Ivana, Howell, Anthony, Powles, Trevor J., Newman, William G., Dowsett, Mitchell
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Clinical Oncology 2017
Materias:	ORIGINAL REPORTS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455424/ https://www.ncbi.nlm.nih.gov/pubmed/28029312 http://dx.doi.org/10.1200/JCO.2016.69.8944

Ejemplares similares

Tamoxifen related side effects and their impact on breast cancer incidence: A retrospective analysis of the randomised IBIS-I trial
por: Hale, Michael J., et al.
Publicado: (2020)

SNPs for breast cancer risk assessment
por: Cuzick, Jack, et al.
Publicado: (2017)

Retrospective analysis of molecular scores for the prediction of distant recurrence according to baseline risk factors
por: Sestak, Ivana, et al.
Publicado: (2016)

Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial
por: Cuzick, Jack, et al.
Publicado: (2015)

A case–control evaluation of 143 single nucleotide polymorphisms for breast cancer risk stratification with classical factors and mammographic density
por: Brentnall, Adam R., et al.
Publicado: (2019)

Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial
por: Sestak, I, et al.
Publicado: (2012)

Factors Predicting Late Recurrence for Estrogen Receptor–Positive Breast Cancer
por: Sestak, Ivana, et al.
Publicado: (2013)

The importance of ethnicity: Are breast cancer polygenic risk scores ready for women who are not of White European origin?
por: Evans, D. Gareth, et al.
Publicado: (2021)

Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer
por: Buus, Richard, et al.
Publicado: (2018)

Impact of preventive therapy on the risk of breast cancer among women with benign breast disease
por: Cuzick, Jack, et al.
Publicado: (2015)

Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy
por: Buus, Richard, et al.
Publicado: (2016)

Risk Models for Breast Cancer and Their Validation
por: Brentnall, Adam R., et al.
Publicado: (2020)

The impact of body mass index on breast cancer incidence among women at increased risk: an observational study from the International Breast Intervention Studies
por: Smith, Samuel G., et al.
Publicado: (2021)

Chemoprevention: beyond tamoxifen
por: Cuzick, J
Publicado: (2005)

Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen?
por: Cuzick, J, et al.
Publicado: (2006)

Clinical validity of clinical treatment score 5 (CTS5) for estimating risk of late recurrence in unselected, non-trial patients with early oestrogen receptor-positive breast cancer
por: Richman, Juliet, et al.
Publicado: (2020)

Markers for the identification of late breast cancer recurrence
por: Sestak, Ivana, et al.
Publicado: (2015)

Participant-Reported Symptoms and Their Effect on Long-Term Adherence in the International Breast Cancer Intervention Study I (IBIS I)
por: Smith, Samuel George, et al.
Publicado: (2017)

Distribution of breast cancer risk from SNPs and classical risk factors in women of routine screening age in the UK
por: Brentnall, A R, et al.
Publicado: (2014)

Effects of cyclin D(1 )gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study
por: Lundgren, Katja, et al.
Publicado: (2012)

BRCA1, BRCA2 and pedigree genetic analysis to determine genetic risk in the UK Royal Marsden Hospital tamoxifen prevention trial
por: Kote-Jarai, Z, et al.
Publicado: (2000)

Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial
por: Cuzick, Jack, et al.
Publicado: (2020)

Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic
por: Donnelly, L S, et al.
Publicado: (2014)

Mammographic density change in a cohort of premenopausal women receiving tamoxifen for breast cancer prevention over 5 years
por: Brentnall, Adam R., et al.
Publicado: (2020)

Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor–Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5
por: Dowsett, Mitch, et al.
Publicado: (2018)

Breast cancer pathology and stage are better predicted by risk stratification models that include mammographic density and common genetic variants
por: Evans, D. Gareth R., et al.
Publicado: (2019)

Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial
por: Cuzick, Jack, et al.
Publicado: (2010)

Haemostatic changes and thromboembolic risk during tamoxifen therapy in normal women.
por: Jones, A. L., et al.
Publicado: (1992)

Off-treatment bone mineral density changes in postmenopausal women receiving anastrozole for 5 years: 7-year results from the IBIS-II prevention trial
por: Sestak, Ivana, et al.
Publicado: (2021)

Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia
por: Sestak, Ivana, et al.
Publicado: (2019)

Tamoxifen evolution
por: Howell, A., et al.
Publicado: (2023)

Long-term Accuracy of Breast Cancer Risk Assessment Combining Classic Risk Factors and Breast Density
por: Brentnall, Adam R., et al.
Publicado: (2018)

Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial
por: Forbes, John F, et al.
Publicado: (2016)

Preventative therapies for healthy women at high risk of breast cancer
por: Sestak, Ivana
Publicado: (2014)

Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data
por: Cuzick, Jack, et al.
Publicado: (2013)

Mammographic breast density refines Tyrer-Cuzick estimates of breast cancer risk in high-risk women: findings from the placebo arm of the International Breast Cancer Intervention Study I
por: Warwick, Jane, et al.
Publicado: (2014)

Molecular Drivers of Oncotype DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study
por: Buus, Richard, et al.
Publicado: (2021)

Risk factors. Introduction to Session 1
por: Howell, Anthony, et al.
Publicado: (2009)

Measurement of S-phase fraction and ploidy in sequential fine-needle aspirates from primary human breast tumours treated with tamoxifen.
por: Fernando, I. N., et al.
Publicado: (1994)

Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II
por: Sestak, I, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_07qjutltjt64pj2kd290el2uga